Table 1.
Study parameters recorded in the spreadsheet.
Fig 1.
The number of visceral leishmaniasis clinical trials identified in searches of clinical trial registries and publication databases.
Fig 2.
Size, location and date of visceral leishmaniasis clinical trials.
A: The histogram shows the size distribution of visceral leishmaniasis clinical trials. Bars are coloured according to the region in which the trials were conducted. B: The cumulative enrolment of patients into clinical trials is shown as a function of the year in which the trial results were published. Data are divided according to the location at which the patients were enrolled.
Table 2.
The geographical distribution of studies and patients by country.
Fig 3.
The number of patients treated with each drug in visceral leishmaniasis clinical studies.
Bars are coloured according to the region in which the trials were conducted.
Fig 4.
The temporal distribution of clinical trials on visceral leishmaniasis drugs.
The cumulative enrolment of patients into clinical studies of VL drugs is shown as a function of the year in which the trial results were published.
Fig 5.
Bar chart showing dose regimens used in visceral leishmaniasis clinical studies.
Bars show the number of patients treated with the drug in visceral leishmaniasis clinical studies. Bars are colored according to the dose regimen.
Table 3.
The drugs and dose regimens used in visceral leishmaniasis clinical studies.
Fig 6.
Pie chart and table showing the design and method of patient allocation in published visceral leishmaniasis clinical studies.
Fig 7.
Pie chart and table showing diagnostic methods used in published visceral leishmaniasis clinical studies and the number of patients diagnosed by each method.
Fig 8.
Box plot showing duration of follow-up in VL studies.
The majority of studies (104 studies, 21,070 patients) had a follow-up duration of six months. Two studies (406 patients) had a nine month follow-up duration and 24 studies (4,546 patients) had a one year follow-up duration.